16 February 2021    /    News

Zent2U announces the completion of development on Perindopril Arginine tablets

February 16, 2021: Zent2U is happy to announce successful completion of the development on ACE inhibitor Perindopril Arginine. Following positive results of pivotal bioequivalence study performed at Canadian CRO with Coversum Arginine® reference product by Servier® and complying stability data generated on registration batches of the product, we compiled EU CTD dossier which is available for review now. 

Having all studies completed and our dossier compiled we’re targeting to file registration at the earliest possible slot. We believe that having a dossier in place now  grants Zent2U and its partners the great position to register in all relevant European markets at the earliest possible time, and therefore launch the product as soon as exclusivity expires.


Disclaimer: Perindopril Arginine which is subject to patent protection is currently not offered or made available in countries where patents are in force


Partner up now and connect with our team today!


Tomas Pilarcik

Key Account Manager

Thomas Koene

Head of Growth Partnerships



Click here to discover Zent2U


Media Contact

Mounira Lemoui
Head of Communications
U kabelovny 529/16, Dolní MÄ›cholupy, 102 00 Prague 10
Mobil: (+420) 727 873 159